Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:BGNE

BeiGene (BGNE) Stock Price, News & Analysis

BeiGene logo

About BeiGene Stock (NASDAQ:BGNE)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$174.72
$217.22
52-Week Range
N/A
Volume
331,608 shs
Average Volume
342,033 shs
Market Capitalization
$18.03 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$270.75
Consensus Rating
Buy

Company Overview

BeiGene Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
26th Percentile Overall Score

BGNE MarketRank™: 

BeiGene scored higher than 26% of companies evaluated by MarketBeat, and ranked 834th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BeiGene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    BeiGene has received no research coverage in the past 90 days.

  • Read more about BeiGene's stock forecast and price target.
  • Earnings Growth

    Earnings for BeiGene are expected to grow in the coming year, from ($5.64) to ($0.25) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BeiGene is -22.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BeiGene is -22.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Short Interest

    There is no current short interest data available for BGNE.
  • Dividend Yield

    BeiGene does not currently pay a dividend.

  • Dividend Growth

    BeiGene does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for BGNE.
  • MarketBeat Follows

    Only 1 people have added BeiGene to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BeiGene insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.43% of the stock of BeiGene is held by insiders.

  • Percentage Held by Institutions

    48.55% of the stock of BeiGene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about BeiGene's insider trading history.
Receive BGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BGNE Stock News Headlines

Take a look at this picture ...
A strange investment secret — discovered just a few short weeks before this image was taken — correctly predicted it all. Even crazier, this secret accurately called every major financial event in recent history … Now it's signaling something very scary is about to hit the market again …tc pixel
See More Headlines

BGNE Stock Analysis - Frequently Asked Questions

BeiGene, Ltd. (NASDAQ:BGNE) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($1.15) EPS for the quarter, missing analysts' consensus estimates of ($1.11) by $0.04. The business's revenue was up 28.2% on a year-over-year basis.

BeiGene (BGNE) raised $126 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

BeiGene's top institutional shareholders include Group One Trading LLC, Jane Street Group LLC, Arrowpoint Investment Partners Singapore Pte. Ltd. and JPMorgan Chase & Co.. Insiders that own company stock include Advisors Ltd Hhlr, Lai Wang, Bros Advisors Lp Baker, Xiaodong Wang, Xiaobin Wu, Titus B Ball, Julia Aijun Wang, John Oyler, Corazon (Corsee) D Sanders and Chan Henry Lee.
View institutional ownership trends
.

Based on aggregate information from My MarketBeat watchlists, some other companies that BeiGene investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), ServiceNow (NOW) and Saia (SAIA).

Company Calendar

Last Earnings
11/12/2024
Today
8/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BGNE
CIK
1651308
Fax
N/A
Employees
9,000
Year Founded
2010

Price Target and Rating

High Price Target
$300.00
Low Price Target
$235.00
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($8.24)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$881.71 million
Net Margins
-25.94%
Pretax Margin
-24.07%
Return on Equity
-25.12%
Return on Assets
-14.95%

Debt

Debt-to-Equity Ratio
0.05
Current Ratio
1.93
Quick Ratio
1.72

Sales & Book Value

Annual Sales
$3.32 billion
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$37.10 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
97,618,000
Free Float
90,195,000
Market Cap
$18.03 billion
Optionable
Optionable
Beta
0.57

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:BGNE) was last updated on 8/30/2025 by MarketBeat.com Staff
From Our Partners